Avacta Group Plc Share Price London S.E.
Equities
GB0033519546
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- GBX | - |
Sales 2023 | 23.25M 29.61M 2.32B | Sales 2024 * | 24.5M 31.2M 2.45B | Capitalization | 157M 200M 15.67B |
---|---|---|---|---|---|
Net income 2023 | -24M -30.57M -2.4B | Net income 2024 * | -27M -34.39M -2.7B | EV / Sales 2023 | 14 x |
Net cash position 2023 * | 16.2M 20.63M 1.62B | Net cash position 2024 * | 3.01M 3.84M 301M | EV / Sales 2024 * | 6.27 x |
P/E ratio 2023 |
-12.7
x | P/E ratio 2024 * |
-5.7
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 70.66% |
Latest transcript on Avacta Group Plc
Managers | Title | Age | Since |
---|---|---|---|
Tony Gardiner
DFI | Director of Finance/CFO | 53 | 03/01/16 |
Matt Johnson
CTO | Chief Tech/Sci/R&D Officer | - | 15/09/13 |
Michael Vinegrad
IRO | Public Communications Contact | - | 31/05/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Trevor Nicholls
BRD | Director/Board Member | 67 | 01/08/13 |
Tony Gardiner
DFI | Director of Finance/CFO | 53 | 03/01/16 |
Paul Fry
BRD | Director/Board Member | 58 | 02/02/20 |
1st Jan change | Capi. | |
---|---|---|
+12.30% | 116B | |
+12.15% | 106B | |
-8.14% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-15.33% | 16.33B | |
+5.80% | 14.14B | |
+28.03% | 12.02B |